Louise Rodino-Klapac
Known title: Chief Scientific OfficerCIK: 0001836218
Louise Rodino-Klapac's purchase track record
Louise Rodino-Klapac has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2021 | SRPT | $300K | -9.1% | -15.4% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SRPT | ▼ Sell | Tax Withholding | 21,423 | $476K | 9/4/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 948 | $16K | 3/11/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 895 | $15K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 504 | $9K | 3/9/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 3,718 | $60K | 3/2/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 767 | $12K | 3/2/2026 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 8,125 | — | 3/1/2026 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 4,582 | $84K | 11/17/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 93,875 | $0 | 9/3/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 50,000 | $0 | 9/3/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 2,539 | $254K | 3/10/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 924 | $93K | 3/10/2025 | View on chart |
| SRPT | ▲ Buy | Grant | 8,276 | — | 3/10/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 514 | $53K | 3/7/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 7,990 | $829K | 3/7/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 5,500 | — | 3/7/2025 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 17,500 | — | 3/6/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,704 | $173K | 3/4/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 715 | $74K | 3/3/2025 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 4,558 | $469K | 11/18/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 2,182 | $359K | 6/24/2024 | View on chart |
| SRPT | ▲ Buy | Option Exercise | 6,250 | — | 6/21/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 909 | $112K | 3/8/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 512 | $62K | 3/7/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,728 | $217K | 3/4/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 778 | $98K | 3/1/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 6,000 | $0 | 3/1/2024 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 4,508 | $374K | 11/17/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 912 | $140K | 3/8/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,134 | $178K | 3/6/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 4,500 | $0 | 3/6/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 522 | $77K | 3/1/2023 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 4,211 | $457K | 11/17/2022 | View on chart |
| SRPT | ▲ Buy | Grant | 8,000 | $0 | 3/7/2022 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 1,216 | $96K | 3/4/2022 | View on chart |
| SRPT | ▼ Sell | Tax Withholding | 572 | $43K | 3/1/2022 | View on chart |
| SRPT | ▲ Buy | Open Market | 3,780 | $300K | 11/24/2021 | View on chart |
| SRPT | ▲ Buy | Grant | 40,000 | $0 | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.